Skip to main content

Table 5 Scenario analysis cost and outcomes when considering direct effects only

From: Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada

Outcome PCV13 PCV10 Difference (PCV13 – PCV10)
Total life-years 605,587,157 605,586,870 287.45
  Total QALYs 543,278,132 543,264,303 257.70
Annual number of cases
  Myringotomy 1,906 1,918 −11.0
  Neurological impairment 35.7 35.8 −0.1
  Hearing loss 66.3 66.5 −0.2
  Death 10,466.50 10,480.47 −14.0
  Annual direct medical costs $1,312,418,621 $1,318,177,638 –$5,759,017
Cost per QALY PCV13 dominates PCV10
  1. PCV10 10-valent pneumococcal conjugate vaccine; PCV13 13-valent pneumococcal conjugate vaccine; QALY quality-adjusted life-year.